Alx Oncology Holdings (ALXO) Interest Expenses (2019 - 2026)
Alx Oncology Holdings recorded quarterly Interest Expenses of $331000.0 in Q1 2026, down 13.58% quarter-over-quarter from $383000.0 in Q4 2025, and down 18.47% year-over-year from $406000.0 in Q1 2025.
Alx Oncology Holdings' Interest Expenses history runs 7 years deep, the most recent figure standing at $331000.0 for Q1 2026.
- In Q1 2026, Interest Expenses fell 18.47% year-over-year to $331000.0; the TTM figure through Mar 2026 stood at $1.5 million (down 10.6% YoY), while the FY2025 annual figure was $1.6 million, down 7.35% from the prior year.
- Interest Expenses came in at $331000.0 for Q1 2026 at Alx Oncology Holdings, down from $383000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $446000.0 in Q3 2024 to a low of $2000.0 in Q2 2022.
- A 5-year average of $321470.6 and a median of $391000.0 in 2023 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses surged 19450.0% in 2023 and fell 18.47% in 2026, its largest moves.
- Alx Oncology Holdings' Interest Expenses stood at $231000.0 in 2022, then soared by 79.65% to $415000.0 in 2023, then advanced by 2.89% to $427000.0 in 2024, then decreased by 10.3% to $383000.0 in 2025, then fell by 13.58% to $331000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $331000.0, $383000.0, and $408000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 331,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 331,000.00 |
| Mar 31, 2026 | 331,000.00 |
| Dec 31, 2025 | 383,000.00 |
| Dec 31, 2025 | 383,000.00 |
| Sep 30, 2025 | 408,000.00 |
| Sep 30, 2025 | 408,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Mar 31, 2025 | 406,000.00 |
| Mar 31, 2025 | 406,000.00 |
| Dec 31, 2024 | 427,000.00 |
| Dec 31, 2024 | 427,000.00 |
| Sep 30, 2024 | 446,000.00 |
| Sep 30, 2024 | 446,000.00 |
| Jun 30, 2024 | 429,000.00 |
| Jun 30, 2024 | 429,000.00 |
| Mar 31, 2024 | 427,000.00 |
| Mar 31, 2024 | 427,000.00 |
| Dec 31, 2023 | 415,000.00 |
| Dec 31, 2023 | 415,000.00 |
| Sep 30, 2023 | 391,000.00 |
| Sep 30, 2023 | 391,000.00 |
| Jun 30, 2023 | 372,000.00 |
| Jun 30, 2023 | 372,000.00 |
| Mar 31, 2023 | 387,000.00 |
| Mar 31, 2023 | 387,000.00 |
| Dec 31, 2022 | 231,000.00 |
| Dec 31, 2022 | 231,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 2,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2020 | -5,000.00 |
| Dec 31, 2020 | -5,000.00 |
| Sep 30, 2020 | 111,000.00 |
| Sep 30, 2020 | 111,000.00 |
| Jun 30, 2020 | 305,000.00 |
| Jun 30, 2020 | 305,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Sep 30, 2019 | 2,000.00 |
| Sep 30, 2019 | 2,000.00 |